Isatuximab Plus VRd Wins Japanese Approval for Transplant-Ineligible, Newly Diagnosed Myeloma
FDA Grants Priority Review to Perioperative Pembrolizumab in Resectable HNSCC
MD Anderson Receives Nearly $23 Million in CPRIT Funding for Cancer Research, Faculty Recruitment
Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC